NCT02161679View on ClinicalTrials.gov

Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 31, 2016

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
Triple-negative Breast Cancer
Interventions
DRUG

IMMU-132 infusion is administered to participants in one arm for the study

DRUG

IMMU-132 plus Carboplatin infusion

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT02161679 - Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer | Biotech Hunter | Biotech Hunter